Genovis AB (publ.)

OM:GENO Stock Report

Market Cap: SEK 1.6b

Genovis AB (publ.) Valuation

Is GENO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GENO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GENO (SEK25) is trading above our estimate of fair value (SEK22.44)

Significantly Below Fair Value: GENO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GENO?

Key metric: As GENO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GENO. This is calculated by dividing GENO's market cap by their current earnings.
What is GENO's PE Ratio?
PE Ratio58.6x
EarningsSEK 27.91m
Market CapSEK 1.64b

Price to Earnings Ratio vs Peers

How does GENO's PE Ratio compare to its peers?

The above table shows the PE ratio for GENO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average67x
MAGLE Magle Chemoswed Holding
36.5xn/aSEK 610.9m
MCAP MedCap
39xn/aSEK 8.9b
BIOT Biotage
49.5x19.5%SEK 12.7b
ALIF B AddLife
142.9x52.0%SEK 16.7b
GENO Genovis AB (publ.)
58.6x16.4%SEK 1.6b

Price-To-Earnings vs Peers: GENO is good value based on its Price-To-Earnings Ratio (58.6x) compared to the peer average (67x).

Price to Earnings Ratio vs Industry

How does GENO's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
GENO 58.6xIndustry Avg. 38.2xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GENO is expensive based on its Price-To-Earnings Ratio (58.6x) compared to the European Life Sciences industry average (38.6x).

Price to Earnings Ratio vs Fair Ratio

What is GENO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GENO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio58.6x
Fair PE Ratio33.7x

Price-To-Earnings vs Fair Ratio: GENO is expensive based on its Price-To-Earnings Ratio (58.6x) compared to the estimated Fair Price-To-Earnings Ratio (33.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GENO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 25.00
SEK 39.00
+56.0%
25.7%SEK 53.00SEK 30.00n/a3
Dec ’25SEK 26.25
SEK 39.00
+48.6%
25.7%SEK 53.00SEK 30.00n/a3
Nov ’25SEK 21.75
SEK 38.00
+74.7%
26.8%SEK 52.00SEK 28.00n/a3
Oct ’25SEK 26.05
SEK 43.00
+65.1%
20.9%SEK 52.00SEK 34.00n/a2
Sep ’25SEK 25.30
SEK 43.00
+70.0%
20.9%SEK 52.00SEK 34.00n/a2
Aug ’25SEK 29.00
SEK 51.50
+77.6%
26.2%SEK 65.00SEK 38.00n/a2
Jul ’25SEK 27.70
SEK 51.50
+85.9%
26.2%SEK 65.00SEK 38.00n/a2
Jun ’25SEK 38.25
SEK 51.50
+34.6%
26.2%SEK 65.00SEK 38.00n/a2
May ’25SEK 27.85
SEK 50.50
+81.3%
24.8%SEK 63.00SEK 38.00n/a2
Apr ’25SEK 33.40
SEK 55.50
+66.2%
13.5%SEK 63.00SEK 48.00n/a2
Mar ’25SEK 38.35
SEK 68.00
+77.3%
10.3%SEK 75.00SEK 61.00n/a2
Feb ’25SEK 52.40
SEK 75.67
+44.4%
9.0%SEK 81.00SEK 66.00n/a3
Jan ’25SEK 52.00
SEK 75.67
+45.5%
9.0%SEK 81.00SEK 66.00n/a3
Dec ’24SEK 49.70
SEK 75.67
+52.2%
9.0%SEK 81.00SEK 66.00SEK 26.253
Nov ’24SEK 43.90
SEK 80.33
+83.0%
14.7%SEK 95.00SEK 66.00SEK 21.753
Oct ’24SEK 46.40
SEK 80.33
+73.1%
14.7%SEK 95.00SEK 66.00SEK 26.053
Sep ’24SEK 52.70
SEK 87.50
+66.0%
8.6%SEK 95.00SEK 80.00SEK 25.302
Aug ’24SEK 47.75
SEK 85.50
+79.1%
6.4%SEK 91.00SEK 80.00SEK 29.002
Jul ’24SEK 47.15
SEK 85.50
+81.3%
6.4%SEK 91.00SEK 80.00SEK 27.702
Jun ’24SEK 52.60
SEK 85.50
+62.5%
6.4%SEK 91.00SEK 80.00SEK 38.252
May ’24SEK 59.10
SEK 82.00
+38.7%
8.5%SEK 89.00SEK 75.00SEK 27.852
Apr ’24SEK 66.30
SEK 82.00
+23.7%
8.5%SEK 89.00SEK 75.00SEK 33.402
Mar ’24SEK 57.20
SEK 82.00
+43.4%
8.5%SEK 89.00SEK 75.00SEK 38.352
Feb ’24SEK 62.00
SEK 76.00
+22.6%
7.9%SEK 82.00SEK 70.00SEK 52.402
Jan ’24SEK 45.95
SEK 71.00
+54.5%
15.5%SEK 82.00SEK 60.00SEK 52.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 05:02
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genovis AB (publ.) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel AlbinDanske Bank
Simon LarssonDanske Bank
Josefine PerssonNordea Markets